Roots Analysis
Antibody Contract Manufacturing Market is Expected to Reach 17 billion by 2030
Next Generation Immune Checkpoint Inhibitors and Stimulators Market Research Report 2019-2030
Roots Analysis has done a detailed study on Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
- More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indications
- The pipeline features a variety of marketed / clinical stage therapies, targeting a number of different types of immune checkpoints and being investigated for administration via different routes
- In the last few years, over 600 clinical studies of various types of immune checkpoint modulation-based therapies, involving nearly 90,000 patients across different centers / hospitals, have been initiated worldwide
- In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, developers are actively exploring the therapeutic potential of novel immune checkpoints, beyond PD-L1, PD-1 and CTLA-4
- Over time, big pharma players have initiated product development programs focused on immune checkpoint modulation for treating various oncological indications, investing significant capital, time and effort
- Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets
- The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders
- The future market, based on the revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across different disease areas, mechanisms and key geographical regions
- In the long term, the opportunity is likely to be segmented across diverse therapeutic modalities, immune checkpoint targets and routes of administration
Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Table of Contents
- PREFACE
- Scope of the Report
- Research Methodology
- Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
- Chapter Overview
- Introduction to Cancer Immunotherapy
- Fundamentals of Cancer Immunotherapy
- Immune Checkpoint Modulators
- First Generation Immune Checkpoint Modulators
- Next Generation Immune Checkpoint Modulators
- Types of Next Generation Immune Checkpoint Modulators
- Challenges-related to Immune Checkpoint Modulation-based Therapy
- Future Perspectives
- CURRENT MARKET LANDSCAPE: CLINICAL AND PRECLINICAL MOLECULES
- Chapter Overview
4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
- Next Generation Immune Checkpoint Inhibitors and Stimulators: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Immune Checkpoint
4.3.3. Analysis by Mechanism of Action
4.3.4. Analysis by Therapeutic Modality
4.3.5. Analysis by Route of Administration
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Therapeutic Area
4.3.8. Analysis by Type of Therapy
4.3.9. Funnel Representation: Analysis by Phase of Development, Mechanism of Action and Type of Therapy
- Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developer Companies: Analysis by Number of Pipeline Therapies
4.4.4. World Map Representation: Analysis by Geography
- MARKET LANDSCAPE: THERAPIES TARGETING CD47
- Chapter Overview
5.2. Next Generation Immune Checkpoint Inhibitors: Development Pipeline of CD47 Targeting Therapies
- Next Generation Immune Checkpoint Inhibitors: Pipeline Analysis of CD47 Targeting Therapies
5.3.1. Analysis by Phase of Development
5.3.2. Analysis by Therapeutic Modality
5.3.3. Analysis by Route of Administration
5.3.4. Analysis by Target Disease Indication
5.3.5. Analysis by Type of Therapy
5.4. Next Generation Immune Checkpoint Inhibitors: List of Companies Developing CD47 Targeting Therapies
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size and Geographical Location
5.4.3. Leading Developers: Analysis by Number of Therapies
5.4.4. World Map Representation: Analysis by Geography
- MARKET LANDSCAPE: THERAPIES TARGETING 4-1BB
- Chapter Overview
6.2. Next Generation Immune Checkpoint Stimulators: Development Pipeline of 4-1BB Targeting Therapies
6.3. Next Generation Immune Checkpoint Stimulators: Pipeline Analysis of 4-1BB Targeting Therapies
6.3.1. Analysis by Phase of Development
6.3.2. Analysis by Therapeutic Modality
6.3.3. Analysis by Route of Administration
6.3.4. Analysis by Target Disease Indication
6.3.5. Analysis by Type of Therapy
6.4. Next Generation Immune Checkpoint Stimulators: List of Companies Developing 4-1BB Targeting Therapies
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Company Size and Geographical Location
6.4.3. Leading Developers: Analysis by Number of Therapies
6.4.4. World Map Representation: Analysis by Geography
- CLINICAL TRIAL ANALYSIS
- Chapter Overview
- Scope and Methodology
- Next Generation Immune Checkpoint Inhibitors and Stimulators: Clinical Trial Analysis
- Analysis by Trial Registration Year
- Analysis by Trial Phase
- Analysis by Trial Recruitment Status
- Analysis by Trial Registration Year and Number of Patients Enrolled
- Analysis by Study Design
- Analysis by Sponsor / Collaborator
- Leading Industry Sponsors: Analysis by Number of Registered Trials
- Word Cloud: Key Focus Areas
- Analysis by Target Immune Checkpoint
- Analysis by Target Therapeutic Area
- Popular Interventions: Analysis by Number of Registered Trials
- Geographical Analysis by Number of Registered Trials
- Geographical Analysis by Trial Recruitment Status
- Geographical Analysis by Number of Patients Enrolled
- COMPANY PROFILES: NEXT GENERATION INHIBITORS AND STIMULATORS
- Chapter Overview
- Bristol-Myers Squibb
- Company Overview
- Financial Information
- Next Generation Immune Checkpoint Therapeutics Portfolio
- Recent Developments and Future Outlook
- Eli Lilly
- Company Overview
- Financial Information
- Next Generation Immune Checkpoint Therapeutics Portfolio
- Recent Developments and Future Outlook
- GlaxoSmithKline
- Company Overview
- Financial Information
- Next Generation Immune Checkpoint Therapeutics Portfolio
- Recent Developments and Future Outlook
- Novartis
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.4.4. Recent Developments and Future Outlook
- XOMA
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.5.4. Recent Developments and Future Outlook
- ACADEMIC GRANTS ANALYSIS
- Chapter Overview
- Scope and Methodology
9.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Analysis of Grants Awarded by the National Institutes of Health (NIH)
9.3.1. Analysis by Year of Grant Award
9.3.2. Analysis by Amount Awarded
9.3.3. Analysis by Administering Institute Center
9.3.4. Analysis by Funding Institute Center
9.3.5. Analysis by Support Period
9.3.6. Analysis by Funding Institute Center and Support Period
9.3.7. Analysis by Type of Grant Application
9.3.8. Analysis by Purpose of Grant Award
9.3.9. Analysis by Grant Mechanism
9.3.10. Word Cloud: Emerging Focus Areas
9.3.11. Popular Target Immune Checkpoints: Analysis by Number of Grants
9.3.12. Analysis of Grant Amount Awarded by Target Immune Checkpoints
9.3.13. Analysis by Study Section Involved
9.3.14. Analysis by Types of Recipient Organizations
9.3.15. Popular Recipient Organizations: Analysis by Number of Grants
9.3.16. Prominent Program Officers: Analysis by Number of Grants
9.3.17. Regional Analysis of Recipient Organizations
- Grant Attractiveness Analysis
- PARTNERSHIPS AND COLLABORATIONS
- Chapter Overview
- Partnership Models
10.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Target Immune Checkpoint
10.3.4. Analysis by Year of Partnership and Target Immune Checkpoint
10.3.5. Analysis by Type of Partnership and Target Immune Checkpoint
10.3.6. Analysis by Type of Partnership and Target Disease Indication
10.3.7. Analysis by Year and Type of Partner
10.3.8. Most Active Players: Analysis by Number of Partnerships
10.3.9. Regional Analysis
10.3.10. Intercontinental and Intracontinental Agreements
- TARGET COMPETITIVENESS ANALYSIS
- Chapter Overview
- Scope and Methodology
11.3. Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors and Stimulators
11.3.1. Four-Dimensional Bubble Analysis
11.3.2. Five-Dimensional Spider Web Analysis
- BIG PHARMA INITIATIVES
- Chapter Overview
- Big Pharma Initiatives Focused on Next Generation Immune Checkpoint
- Analysis by Number of Initiatives
- Analysis by Product Development Strategy
- Analysis by Target Immune Checkpoint Modulators
- Grid Representation: Analysis by Product Development Strategy and Target Immune Checkpoint
- Analysis by Therapeutic Area
- MARKET FORECAST AND OPPORTUNITY ANALYSIS
- Chapter Overview
- Forecast Methodology and Key Assumptions
- Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030
13.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Individual Product Sales Forecasts
13.4.1. DARZALEX® (Janssen Pharmaceuticals)
13.4.2. GSK3359609 (GlaxoSmithKline)
13.4.3. RRx-001 (EpicentRx)
13.4.4. SAR650984 (Sanofi)
13.4.5. MGA271 (MacroGenics)
13.4.6. Omburtamab (Y-mAbs Therapeutics)
13.4.7. AMG557 (Amgen)
13.4.8. APX005M (Apogenix)
13.4.9. BI 655064 (Boehringer Ingelheim)
13.4.10. Dapirolizumab Pegol (UCB Pharma)
13.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region
13.5.1. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in North America, 2020- 2030
13.5.2. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Europe, 2020-2030
13.5.3. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Asia-Pacific, 2020- 2030
13.5.4. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Rest of the World, 2020-2030
13.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication
13.6.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, 2020-2030
13.6.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, 2020-2030
13.6.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Hematological Malignancies, 2020-2030
13.6.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, 2020-2030
13.6.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, 2020-2030
13.6.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, 2020-2030
13.6.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non- Oncological Indications, 2020-2030
13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint
13.7.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, 2020-2030
13.7.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, 2020-2030
13.7.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, 2020-2030
13.7.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, 2020-2030
13.7.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, 2020-2030
13.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action
13.8.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, 2020-2030
13.8.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, 2020-2030
13.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality
13.9.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Antibody Fragments, 2020-2030
13.9.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibodies, 2020-2030
13.9.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecule Drugs, 2020-2030
13.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy
13.10.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, 2020-2030
13.10.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, 2020-2030
13.10.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, 2020- 2030
13.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration
13.11.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, 2020-2030
13.11.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, 2020-2030
13.11.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, 2020-2030
- CONCLUDING REMARKS
- EXECUTIVE INSIGHTS
- APPENDIX 1: TABULATED DATA
- APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Global Biopharmaceutical Contract Manufacturing Market Report Forecast by Development, Trends, and Forecast (2019 – 2030)
)
Biopharmaceutical Contract Manufacturing Market Analysis, opportunities Trends and Industry Strategies 2019 – 2030
Antibody Contract Manufacturing Market Analysis and Forecast to 2030
Next Generation Immune Checkpoint Inhibitors and Stimulators Market is Expected to Reach 12.5 billion by 2030
Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions
Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
- A detailed assessment of the current market landscape of drug developers engaged in the development of next generation immune checkpoint modulators.
- A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators.
- Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products).
- An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
- An analysis of the partnerships that have been established in this domain, in the recent past.
- A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
- An analysis of the initiatives of big biopharma players engaged in this domain.
Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Target Disease Indication
- Breast Cancer
- Chronic Lymphocytic Leukemia
- Colorectal Cancer
- Head and Neck Cancer
- Lung Cancer
- Lupus Nephritis
- Melanoma
- Multiple Myeloma
- Primary Sjögren's Syndrome
- Others
Target Immune Checkpoint
- B7-H3
- CD38
- CD40
- CD47
- Others
Mechanism of Action
- Inhibitory
- Stimulatory
Therapeutic Modality
- Monoclonal Antibody
- Small Molecule
Type of Therapy
- Monotherapy
- Combination Therapy
Route of Administration
- Intravenous
- Subcutaneous
- Others
Key Geographical Region
- North America
- Europe
- Asia-Pacific and the Rest of the World
Key companies covered in the report
- Bristol Myers Squibb
- GlaxoSmithKline
- Incyte
- Novartis
- Trillium Therapeutics
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Continuous Manufacturing Market Analysis, opportunities Trends and Industry Strategies 2019 – 2030
Cell Therapy Manufacturing Market is Projected to Reach USD 11 billion by 2030
Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers
Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030.”
The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing. It focuses on both contract manufacturers, as well as developers with in-house manufacturing facilities, offering in-depth analyses of the various business entities that are engaged in this domain, across different global regions. Amongst other elements, the report includes:
- An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective cell therapy manufacturing capabilities, over the period 2015-2019.
- An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established in the period 2014-2019.
- Informed estimates of the annual commercial and clinical demand for cell therapies, in terms of number of cells produced and area dedicated to manufacturing.
- An estimate of the overall, installed capacity for manufacturing cell-based therapies based on information reported by industry stakeholders in the public domain A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
- A detailed analysis of the various factors that are likely to influence the pricing of cell-based therapies, featuring different models / approaches that may be adopted by manufacturers while deciding the prices of their proprietary offerings.
- A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
- An elaborate discussion on the role of automation technologies in improving current manufacturing methods.
- A discussion on cell therapy manufacturing regulations across various geographies, including North America, Europe, and Asia Pacific.
- Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services.
- A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under a comprehensive SWOT framework.
Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of therapy
- T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies)
- Dendritic cell therapies
- Tumor cell therapies
- NK cell therapies
- Stem cell therapies
Source of cells
- Autologous
- Allogeneic
Scale of operation
- Clinical
- Commercial
Purpose of manufacturing
- Contract manufacturing
- In-house manufacturing
Key geographical regions
- North America
- Europe
- Asia Pacific
- Rest of the world
Key companies covered in the report
- BioNTech Innovative Manufacturing Services
- Cell Therapies
- Cell and Gene Therapy Catapult
- Center for Cell and Gene Therapy, Baylor College of Medicine
- Centre for Cell Manufacturing Ireland, National University of Ireland
- Clinical Cell and Vaccine Production Facility, University of Pennsylvania
- Cognate BioServices
- FUJIFILM
- Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
- Hitachi Chemical
- KBI Biopharma
- Laboratory for Cell and Gene Medicine, Stanford University
- Lonza
- MaSTherCell
- MEDINET
- Molecular and Cellular Therapeutics, University of Minnesota
- Newcastle Cellular Therapies Facility, Newcastle University
- Nikon CeLL innovation
- Rayne Cell Therapy Suite, King’s College London
- Roslin Cell Therapies
- Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
- Sydney Cell and Gene Therapy
- WuXi Advanced Therapies
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Biopharmaceutical Contract Manufacturing Market Headed for Growth and Global Expansion by 2030
Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages
Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.”
The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:
- A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
- Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
- A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
- A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
- A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
- A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
- An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
- A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
- An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
- An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
- A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
- A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
- A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
- A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
Read Detailed Analysis: https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Commonly Outsourced Business Operations
- Active Pharmaceutical Ingredients (API)
- Finished Dosage Formulations (FDF)
Types of Expression System
- Mammalian
- Microbial
- Others
Company Size
- Small
- Mid-Sized
- Large and Very Large
Scale of Operation
- Preclinical
- Clinical
- Commercial
Key Geographical Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
The report also features detailed transcripts of discussions held with the following experts:
- Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
- Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
- Christian Bailly, Director of CDMO, Pierre Fabre
- Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
- David C Cunningham, Director Corporate Development, Goodwin Biotechnology
- Dietmar Katinger, Chief Executive Officer, Polymun Scientific
- Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
- Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
- Kevin Daley, Director Pharmaceuticals, Novasep
- Mark Wright, Site Head, Grangemouth, Piramal Healthcare
- Nicolas Grandchamp, R&D Leader, GEG Tech
- Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
- Sebastian Schuck, Head of Business Development, Wacker Biotech
- Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
- Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
- Tim Oldham, Chief Executive Officer, Cell Therapies
Key companies covered in the report
- 3P Biopharmaceuticals
- Abzena
- Albany Molecular Research
- BioVectra
- BioXcellence (Boehringer Ingelheim)
- Celonic
- Charles River Laboratories
- ChemPartner
- Cobra Biologics
- CordenPharma
- Cytovance Biologics
- GE Healthcare
- Goodwin Biotechnology
- Grand River Aseptic Manufacturing
- IDT Biologika
- KBI BioPharma
- Kemwell Biopharma
- LFB Biomanufacturing
- Meridian Life Science
- Patheon
- Pfizer CentreOne
- PX'Therapeutics
- Samsung BioLogics
- Sanofi, CEPiA
- Thermo Fisher Scientific
- Vetter Pharma International
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Antibody Contract Manufacturing Market is Expected to Reach 17 billion by 2030
The benefits of engaging a CMO or CDMO for antibody development and production extend beyond fulfilling the needs of small companies; access to new technologies and operational flexibility are attractive attributes to larger players as well
Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.
The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies. The study also features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:
- A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies.
- A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength and service strength.
- A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.
- An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013.
- An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October).
- An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain.
- Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
- Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities.
- A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.
- A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.
Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Antibodies
- Monoclonal Antibodies
- Bispecific Antibodies
- ADCs
- Others
Company Size
- Small
- Mid-sized
- Large / Very Large
Scale of Operation
- Preclinical / Clinical
- Commercial
Type of expression system used
- Mammalian
- Microbial
Key geographical regions
- North America
- Europe
- Asia and RoW
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
- Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
- David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
- Claire Otjes (Marketing Manager, Batavia Biosciences)
Market Key Players:
- AGC Biologics
- Aldevron
- AMRI
- Boehringer Ingelheim BioXcellence
- Emergent BioSolutions
- Eurofins CDMO
- FUJIFILM Diosynth Biotechnologies
- KBI Biopharma
- Lonza
- Nitto Avecia Pharma Services
- Novasep
- Pierre Fabre
- Samsung BioLogics
- Synthon
- Thermo Fisher Scientific
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Targeted Protein Degradation Market Trends 2019 and Industry Forecast 2030
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. Owing to various reasons, conventional pharmacological interventions have been severely restricted in terms of accessing protein targets of pathological significance.
Key Inclusions
- A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.
- Elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history.
- Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.
- A detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.
- An assessment of the relative experience of key opinion leaders (KOLs) within this domain, (shortlisted based on their involvement in various clinical studies), featuring detailed 2X2 matrices (based on the strength and activeness of KOLs), a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
- A detailed publication analysis of more than 210 peer-reviewed, scientific articles that have been published since 2017, highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on novel protein degraders, potential target proteins, target disease indications, and analysis based on various relevant parameters, such as year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.
- An analysis of the partnerships that have been established in the domain, over the period 2014-Q3 2019, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
- An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.
Get detailed Analysis: https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Market Segments:
Type of payment of licensing agreements
- Upfront payments
- Milestone payments
Type of protein degrader
- Degronimids
- PROTACs
- SARDs / SERDs
- Specific BET and DUB inhibitors
- Other protein degraders
Therapeutic area
- Neurodegenerative disorders
- Oncological disorders
- Other therapeutic areas
Route of administration
- Oral
- Intravenous
- Other routes
Key geographical region
- North America
- Europe
- Asia-Pacific
Key Questions Answered
- What are the prevalent R&D trends related to targeted protein degradation?
- Which clinical conditions can be treated using targeted protein degradation-based therapeutics?
- What are the most popular proteins being targeted by bifunctional degrader molecules?
- What are the key challenges faced by stakeholders engaged in this domain?
- What are the key technology platforms that leverage the concept of targeted protein degradation?
- Who are the leading industry and non-industry players in this market?
- What are the contributions of big pharma players in this field?
- What are the key geographies where research on targeted protein degradation is being conducted?
- Who are the key investors in this domain?
- Who are the key opinion leaders / experts in this field?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the factors that are likely to influence the evolution of this upcoming market?
- How is the current and future market opportunity likely to be distributed across key market segments?
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Medical Device Label Contract Manufacturing Market Report – Industry Size, Share, Trends, Growth and Forecast Till 2030
Owing to the ever-increasing number of medical devices along with the rising associated complexities and stringent guidelines issued by various regulatory authorities, the global medical device labeling market is likely to grow at stable rate. Furthermore, it is also necessary for the organizations to adopt labeling practices which can help them to reduce reaction time in order to process change requirements.
Therefore, in order to overcome the aforementioned challenges, medical devices companies are outsourcing their packaging and labeling operations to core label manufacturers.
The USD 509 Million (by 2030) financial opportunity within the medical device label contract manufacturing market has been analyzed across the following segments:
Key Segments:
Type of labels
- Glue applied labels
- Pressure sensitive labels
- In mould labels
- Shrink sleeve labels
- Other labels
Type of material
- Plastic labels
- Paper labels
- Other material labels
Application type
- Monitoring and diagnostic equipment labels
- Disposable consumables labels
- Therapeutic equipment labels
Device class
- Class I medical devices
- Class II medical devices
- Class III medical devices
Key geographical regions
- North America
- Europe
- Asia Pacific
The Medical Device Labels Technology Market, 2019-2030 report features the following companies, which we identified to be key players in this domain:
Market Key Players:
- Avery Dennison
- Faubel
- Huhtamaki
- Iwata Label
- Labeltape
- Matform
- Maverick Label
- Mondi Group
- Multi-Color
- OPM Group
- Resource Label Group
- Schreiner Group
- Steven Label
- Topflight
- WS Packaging
Table of Contents
- Preface
- Executive Summary
- Introduction
- Regulatory Landscape for Medical Device Labeling
- Market Landscape
- Company Profiles
- Mergers and Acquisitions
- Key Acquisitions Targets
- Benchmark Analysis
- Attractive Competition (AC) Matrix
- Market Forecast and Opportunity Analysis
- SWOT Analysis
- Emerging Trends and Opportunities in Medical Device Labeling
- Appendix 1: List of Companies that Offer Labeling Services as a Part of Medical Devices Manufacturing
- Appendix 2: Tabulated Data
- Appendix 3: List of Companies and Organizations Included in the Database / Mentioned in this Report
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/medical-device-labels-manufacturing-market-2019-2030/272.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Non-Invasive Cancer Diagnostics Market Research Report 2019-2030
Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market, 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Inclusions
- A detailed review of the overall landscape of the non-invasive cancer diagnostics market, featuring information on the developers of such products and analyses based on a number of relevant parameters, such as year of establishment, company size, geographical location, current development status of proprietary liquid biopsy test (under development, research use only, and available), type of product (assay kit, software / algorithm and device), type of tumor marker analyzed (CTCs, ctDNA, cfDNA, exosomes, and others), key applications (early diagnosis, treatment selection, patient monitoring and recurrence monitoring), type of analyte used (blood, urine and others) and target cancer indications.
- An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019, based on various parameters, such as type of partnership, year of partnership, type of tumor marker, target cancer indications and the most active players.
- An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics, including details of seed financing, venture capital financing, debt financing, grants, and capital raised via IPOs and subsequent public offerings.
- An analysis of the initiatives of big pharma players, highlighting the key focus areas of such companies and analysis based on various relevant parameters, such as stage of development of their proprietary non-invasive cancer diagnostic test(s), key applications, type of tumor marker and target disease indications.
- A detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2016, and offering a means for other industry stakeholders to identify potential acquisition targets.
- Elaborate profiles of the key players engaged in this domain, featuring a brief overview of the company, its financial information (if available), a detailed description of its product portfolio, recent developments and an informed future outlook
- Informed estimates of the existing market size and the future growth opportunities for non-invasive cancer diagnostics. Based on various parameters, such as number of available / under development products and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030.
For more information, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
The report features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Type of Tumor Marker
- ctDNA
- cfDNA
- CTCs
- Exosomes
- Others
Application
- Diagnosis / Early Diagnosis
- Patient Monitoring
- Recurrence Monitoring
Target Cancer Indication
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Gastric Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
End Users
- Hospitals
- Research Institutes
- Others
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
The report also features inputs from eminent industry stakeholders, according to whom liquid biopsy has the potential to diagnose cancer at a very early stage by analyzing rare circulating tumour markers, thereby, facilitating appropriate / timely treatment decisions. The report includes detailed transcripts of discussions held with the following experts:
- Joachim Fluhrer, Founder and Medical Director, Genostics
- Shibichakravarthy Kannan, Founder and CEO, Theranosis Life Sciences
- Abizar Lakdawalla, Founder, ProXeom
- Philippe Nore, CEO and Co-founder, MiNDERA
- Frank Szczepanski, President and CEO, IVDiagnostics
- Mark Li, CEO, Resolution Bioscience
- Brad Walsh, CEO, Minomic International
- Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations
- Burkhard Jansen, Chief Medical Officer, DermTech
- Christer Ericsson, Chief Scientific Officer, iCellate Medical
- Jake Micallef, Chief Scientific Officer, VolitionRx
- Nathalie Bernard, Marketing Director, OncoDNA
- Riccardo Razzini, Sales and Marketing Manager, LCM Genect
- Peter French, Strategic Technology Advisor, Sienna Cancer Diagnostics
Get Detailed Research Report: https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Key Questions Answered
- What are the prevalent trends within the liquid biopsy market?
- What are the key applications of liquid biopsy?
- Apart from liquid biopsy, what are the other novel non-invasive cancer diagnostics?
- What is the role of big pharma players in the non-invasive cancer diagnostics domain?
- What are the prevalent financing and investment trends within the liquid biopsy market?
- What are the most popular cancer indications for which non-invasive diagnostics are being developed?
- Who are the key service providers for liquid biopsy products?
- How is the current and future market opportunity likely to be distributed across key market segments?
Request for Sample Copy: https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Protein Degradation Market is estimated to be worth over USD 3.6 billion by 2030
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.
The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:
Market Segment:
Type of payment of licensing agreements
- Upfront payments
- Milestone payments
Type of protein degrader
- Degronimids
- PROTACs
- SARDs / SERDs
- Specific BET and DUB inhibitors
- Other protein degraders
Therapeutic area
- Neurodegenerative disorders
- Oncological disorders
- Other therapeutic areas
Route of administration
- Oral
- Intravenous
- Other routes
Key geographical region
- North America
- Europe
- Asia-Pacific
The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:
Market Key Players:
- Arvinas
- Captor Therapeutics
- Celgene
- Genetech
- Kymera Therapeutics
- Mission Therapeutics
- Progenra
- Radius Health
- Sanofi Genzyme
- Zenopharm
Table of Contents
- Preface
- Executive Summary
- Introduction
- Current Market Landscape
- Company Profiles
- Clinical Trial Analysis
- KOL Analysis
- Publication Analysis
- Funding and Investment Analysis
- Partnerships and Collaborations
- Market Sizing and Opportunity Analysis
- Executive Insights
- Concluding Remarks
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Drug Delivery Systems Market Research Report 2019-2030
Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, auto injectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.
The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:
Get Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
Market Segment:
Phase of development
- Approved
- Pre-registration & Phase III
- Phase II & Phase II/III
Type of molecule
- Cell and gene therapies
- Monoclonal antibodies
- Proteins
- Peptides (recombinant)
- Vaccines
- Others
Target therapeutic area
- Autoimmune disorders
- Blood disorders
- Bone disorders
- Genetic disorders
- Metabolic disorders
- Neurological disorders
- Oncological disorders
- Respiratory disorders
- Others
Type of drug delivery system
- Large volume wearable injectors
- Autoinjectors
- Prefilled syringes
- Needle-free injectors
- Drug reconstitution systems
- Revenues from licensing deals
- Upfront payments
- Milestone payments
Key geographical regions
- North America
- Europe
- Asia Pacific
- Rest of the World
The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:
Market Key Players:
- Adocia
- Ajinomoto Bio-Pharma Services
- Arecor
- Alteogen
- Ascendis Pharma
- Avadel Pharmaceuticals
- Camurus
- Creative BioMart
- Creative Biolabs
- DURECT
- Eagle Pharmaceuticals
- Halozyme Therapeutics
- MedinCell
- Xeris Pharmaceuticals
- Serina Therapeutics
Request for Sample: https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
Table of Contents
- Preface
- Executive Summary
- Introduction
- Subcutaneous Biologics: Current Market Landscape
- Case Study: Leading Subcutaneous Biologics
- Subcutaneous Formulation Technologies: Current Market Landscape
- Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis
- Subcutaneous Formulation Technology Developers: Company Profiles
- Partnerships and Collaborations
- Subcutaneous Drug Delivery Systems: Current Market Landscape
- Swot Analysis
- Market Forecast and Opportunity Analysis
- Concluding Remarks
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List Of Companies And Organization
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Medical Device Label Contract Manufacturing Market is Expected to Grow at a CAGR 9.8% by 2030
Roots Analysis has done a detailed study on Medical Device Labels Technology Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
- More than 80 companies presently claim to have the required expertise to design and manufacture different types of labels, using both conventional advanced printing methods, for use in medical devices
- The market landscape is fragmented, featuring the presence of both established players and new entrants; most medical device label manufacturing companies are located in North America
- Label manufacturers are steadily expanding their capabilities in order to enhance their respective service portfolios and upgrade their capabilities to comply to evolving industry benchmarks
- Digital printing technologies have gradually become on of the much sought-after solutions in this industry; further, there are a variety of upcoming opportunities that are anticipated to sustain growth in this domain
- Acquisitions in this domain are largely driven by efforts to enhance the technology portfolio of label manufacturers; key value drivers include geographical consolidation and capability addition
- Driven by a growing demand for different types of labels, the medical device label manufacturing market is likely to grow at a steady pace over the coming years
- The forecasted future opportunity is anticipated to be distributed across different types of labeling materials used, diverse device classes and application areas
For more information, please visit https://www.rootsanalysis.com/reports/view_document/medical-device-labels-manufacturing-market-2019-2030/272.html
Table of Contents
- PREFACE
- Scope of the Report
- Research Methodology
- Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
- Context and Background
- Overview of Medical Device Packaging
- Overview of Medical Device Labeling
- General Labeling Principles
- In Vitro Diagnostic Devices
- Other Medical Devices
3.4.3 Critical Medical Devices
- Software Used as a Medical Device
- Instructions for End Users
- Good Manufacturing Practices (GMP) Labeling Requirements
- Overview of Labels and Label Manufacturing
- Types of Labels
- Types of Label Printing Techniques
- Types of Label Folding Techniques
- Special Label Features
- Roadblocks to Medical Device Label Manufacturing
- Concluding Remarks
- REGULATORY LANDSCAPE FOR MEDICAL DEVICE LABELING
- Chapter Overview
- Regulatory Guidelines in North America
- The US Scenario
- Canadian Scenario
- Regulatory Guidelines in Europe
- Regulatory Guidelines in Asia Pacific and Rest of the World
- Japanese Scenario
- Chinese Scenario
- Indian Scenario
- MARKET LANDSCAPE
- Chapter Overview
- Medical Device Label Manufacturers
- Analysis by Year of Establishment
- Analysis by Company Size
- Analysis by Location of Headquarters
- Analysis by Regulatory Certifications / Accreditations
- Analysis by Printing Techniques Used
- Analysis by Type of Label Manufactured
- Analysis by Type of Material Used
- Analysis by Additional Label Features
- Analysis by Type of Label Folding
- Analysis by Other Services Offered
- COMPANY PROFILES
- Chapter Overview
- Companies Headquartered in North America
- Avery Dennison
- Company Overview
- Financial Information
- Service Portfolio
- Capabilities
- Future Outlook
- Labeltape
- Company Overview
- Service Portfolio
- Future Outlook
- Maverick Label
- Company Overview
- Service Portfolio
- Future Outlook
- Multi-Color
- Company Overview
- Financial Information
- Service Portfolio
- Future Outlook
- Resource Label Group
- Company Overview
- Service Portfolio
- Capabilities
- Future Outlook
- Steven Label
- Company Overview
- Service Portfolio
- Future Outlook
- Topflight
- Company Overview
- Service Portfolio
- Future Outlook
- WS Packaging Group
- Company Overview
- Service Portfolio
- Labeling Equipment
- Future Outlook
- Companies Headquartered in Europe
- Faubel
- Company Overview
- Financial Information
- Service Portfolio
- Future Outlook
- Huhtamaki
- Company Overview
- Financial Information
- Service Portfolio
- Future Outlook
- Matform
- Company Overview
- Service Portfolio
- Future Outlook
- Mondi Group
- Company Overview
- Financial Information
- Service Portfolio
- Future Outlook
- OPM Group
- Company Overview
- Service Portfolio
- Future Outlook
- Schreiner Group
- Company Overview
- Service Portfolio
- Future Outlook
- Companies Headquartered in Asia
- Iwata Label
- Company Overview
- Service Portfolio
- Future Outlook
- Syndicate Label
- Company Overview
- Iwata Label
- Faubel
- Avery Dennison
6.4.2.2 Service Portfolio
- Future Outlook
- MERGERS AND ACQUISITIONS
- Chapter Overview
- Merger and Acquisition Models
- Medical Devices Labeling Companies: Mergers and Acquisitions
- Analysis by Year and Type of Merger and Acquisition
- Analysis by Company Size of Acquired and Acquirer Companies
- Ownership Change Matrix
- Regional Analysis of Merger and Acquisition Activity
- Country-wise Distribution
- Continent-wise Distribution
- Intercontinental and Intracontinental Deals
- Analysis by Key Value Drivers
- Analysis by Key Value Drivers and Year of Acquisition
- Analysis by Markets Served by the Acquired Company
- Analysis by Printing Techniques Used by the Acquired Company
- Analysis by Types of Labels Manufactured by the Acquired Company
- POTENTIAL ACQUISITION TARGETS
- Chapter Overview
- Scope and Methodology
- Potential Strategic Acquisition Targets: Analysis for Resource Label Group
8.3.1 Historical Trend
8.3.2 Top Ten Likely Targets
- Potential Strategic Acquisition Targets: Analysis for ProMach
- Historical Trend
8.4.2 Top Ten Likely Targets
- Potential Strategic Acquisition Targets: Analysis for Huhtamaki
- Historical Trend
8.5.2 Top Ten Likely Targets
- Potential Strategic Acquisition Targets: Analysis for UPM Raflatac
8.6.1 Historical Trend
8.6.2. Top Ten Likely Targets
- Concluding Remarks
- BENCHMARK ANALYSIS
- Chapter Overview
- Methodology
- Region-wise Benchmarking
- North America, Peer Group I
- North America, Peer Group II
- North America, Peer Group III
- Europe, Peer Group IV
- Concluding Remarks
- AC MATRIX
- Chapter Overview
- Scope and Methodology
- Industry Attractiveness Analysis
- Industry Competitiveness Analysis
- GE / McKinsey Matrix
- Concluding Remarks
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/medical-device-labels-manufacturing-market-2019-2030/272.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
